It is my aim to replace all animal tests on pharmacokinetics with artificial intelligence till 2025.

These animal experiments are carried out every day on dogs, monkeys, rats and mice worldwide.

Our research shows that results of animal tests on many drugs are NOT transferable to humans and that expert systems with Artificial Intelligence significantly better evaluate drug uptake in humans.

By applying Artificial Intelligence to learn from previous drug studies in humans and animals (ADME/Tox knowledgebases), expert systems are generated, which not “only” replace animal experiments, but also enable the targeted development of effective drugs in all therapeutic fields (cancer, antibiotics, COVID-19, etc.).

Dr. Wolfgang Boomgaarden    
 

Herbert-Stiller-Award 2021 to Wolfgang Boomgaarden from biotech company PharmaInformatic:
 

Good science needs good funding. Also this year, the nationwide association Doctors Against Animal Experiments is awarding two Herbert Stiller sponsorship prizes worth 20,000 Euros each for innovative, human-relevant, animal-free research.

The winners have now been determined: one award goes to MedUni Vienna and one award is given to the company PharmaInformatic.

Both projects have a very high scientific potential and aim both to improve human medicine and to abolish several painful animal experiments.

Dr. Wolfgang Boomgaarden from PharmaInformatic in Emden has developed computer-aided expert systems that use artificial intelligence (AI) to predict how high their bioavailability, i.e. the concentration in the blood, will be based on the chemical structure of a drug candidates. The Herbert-Stiller-Prize enables Dr. Boomgaarden, based on existing data, to carry out a detailed analysis of the oral bioavailability of over 100 drugs in humans.

“This project will once again make it clear that data from animal experiments cannot be transferred to humans. Furthermore, the results should be an incentive for pharmaceutical companies to use these expert systems instead of animal experiments in order to calculate the effectiveness of their drug candidates faster and more precisely, ”says Dr. Dilyana Filipova, scientist at Doctors Against Animal Experiments.
 

“With the Herbert Stiller Prize, we show how promising and advanced animal-free research is. Both humans and animals will benefit from the results of this scientific work in the long term.

That is why we are calling for a drastic increase in public funding for such first-class cruelty-free research projects, ”said Filipova.

Because, as the association documents, less than 1% of public funding in Germany is still used for this future-oriented research, while 99% is wasted on animal experiments.
 

"We know many active drugs from animal experiments or with in-vitro activity," adds Dr. Boomgaarden. "But they are not available on the market, because drug uptake in humans and animals often differs drastically and as a result they have failed in clinical trials in human."

see Press release of Doctors Against Animal Experiments.

 

Our research findings have shown, that not only ethical and scientific reasons speak against animal testing on drug-uptake. There is a strong commercial interest NOT to trust in results from animal drug-uptake. We found large differences in drug-uptake between animals and humans, which can mislead the development of future drugs, see current blockbuster-drugs with annual sales of at least $5 billion.

Life Science Day 2016:

Dr. Wolfgang Boomgaarden explained how artificial intelligence replaces animal testing. The expert system IMPACT-F to evaluate the uptake of drugs in humans (“oral bioavailability”).
 

 
German Biotechnology Days 2017:
 

Dr. Wolfgang Boomgaarden talked about the replacement of animal tests in drug discovery and development and about the economic & financial advantages if researchers do not carry out and rely on vague animal test results.

© Copyright 2004-2021 PharmaInformatic Boomgaarden. All rights reserved.         Site map         Contact         Terms of Use         Imprint